AMICA1
adhesion molecule, interacts with CXADR antigen 1
AMICA1; adhesion molecule, interacts with CXADR antigen 1; junctional adhesion molecule-like; mCrea7; adhesion molecule AMICA; dendritic cell-specific protein CREA7; dendritic-cell specific protein Crea7; AMICA; Crea7; Gm638; MGC61025; JAML; CREA7-1; CREA7-4;
BST1
bone marrow stromal cell antigen 1
BST1; bone marrow stromal cell antigen 1; ADP-ribosyl cyclase 2; ADP ribosyl cyclase 2; CD157; NAD(+) nucleosidase; BST-1; cADPr hydrolase 2; bone marrow stromal antigen 1; cyclic ADP-ribose hydrolase 2;
Cd180
CD180 antigen
CD180; CD180 antigen; ly-78; lymphocyte antigen 78; radioprotective 105 kDa protein; Ly78; RP105; F630107B15;
CD200
CD200 antigen
CD200; CD200 antigen; OX-2 membrane glycoprotein; MRC OX-2 antigen; antigen identified by monoclonal MRC OX-2; OX2; Mox2;
Cd209b
CD209b antigen
CD209B; CD209b antigen; CD209 antigen-like protein B; DC-SIGNR1; DC-SIGN-related protein 1; OtB7; SIGNR1; mSIGNR1; 1810030I22Rik;
CD226
CD226 antigen
CD226; CD226 antigen; platelet and T cell activation antigen 1; platelet and T-cell activation antigen 1; Pta1; DNAM1; DNAM-1; TLiSA1; BC051526;
CD34
Cd34 CD34 antigen
CD34; CD34 antigen; hematopoietic progenitor cell antigen CD34; cluster designation 34; AU040960;
CD40
CD40 antigen
CD40; CD40 molecule, TNF receptor superfamily member 5; p50; Bp50; CDW40; TNFRSF5; tumor necrosis factor receptor superfamily member 5; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily, member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CD_antigen=CD40; CD40 antigen; Dacetuzumab; 880486-59-9; Teneliximab; 299423-37-3;
CD69
CD69 antigen
CD69; CD69 antigen; early activation antigen CD69; Very Early Activation Antigen; AIM; VEA; AI452015; 5830438K24Rik;
CD70
Cd70 CD70 antigen
CD70; CD70 antigen; CD27-L; CD27 ligand; Ki-24 antigen; tumor necrosis factor ligand superfamily member 7; tumor necrosis factor (ligand) superfamily, member 7; Cd27l; CD27LG; Tnfsf7;
Cd80
CD80 antigen
CD80; CD80 antigen; B71; Ly53; TSA1; Cd28l; Ly-53; MIC17; T-lymphocyte activation antigen CD80; B7 protein; activation B7-1 antigen; B7; BB1; LAB7; CD28LG; CD28LG1; OTTHUMP00000215214; OTTHUMP00000215215; costimulatory factor CD80; CTLA-4 counter-receptor B7.1; B-lymphocyte activation antigen B7; costimulatory molecule variant IgV-CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen);
CD84
CD84 antigen
CD84; CD84 antigen; SLAM family member 5; leukocyte differentiation antigen CD84; signaling lymphocytic activation molecule 5; CDw84; SLAMF5; A130013D22Rik;
CEACAM1
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
CEACAM1; carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein); BGP; carcinoembryonic antigen-related cell adhesion molecule 1; BGP1; CD66a; antigen CD66; CD66a antigen; BGPI; Arcitumomab; CEA-Scan; 154361-48-5;
CEACAM3
carcinoembryonic antigen-related cell adhesion molecule 3
CEACAM3; carcinoembryonic antigen-related cell adhesion molecule 3; CGM1; CD66d; CD66d antigen; carcinoembryonic antigen CGM1; nonspecific cross-reacting antigen; carcinoembryonic antigen gene family member 1; CEA; W264; W282; CD66D; MGC119875;
CEACAM5
carcinoembryonic antigen-related cell adhesion molecule 5
CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100; DKFZp781M2392;
CEACAM6
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)
CEACAM6; carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen); NCA; CEAL; CD66c; carcinoembryonic antigen-related cell; CD66c antigen; Non-specific crossreacting antigen; carcinoembryonic antigen-related cell; adhesion molecule 6; Sulesomab; LeukoScan; 167747-19-5;
CEACAM8
carcinoembryonic antigen-related cell adhesion molecule 8
CEACAM8; carcinoembryonic antigen-related cell adhesion molecule 8; CGM6; CD66b; CD67 antigen; carcinoembryonic antigen CGM6; non-specific cross-reacting antigen NCA-95; carcinoembryonic antigen gene family member 6; CD67; NCA-95;
COL4A3
collagen, type IV, alpha 3 (Goodpasture antigen)
COL4A3; collagen, type IV, alpha 3 (Goodpasture antigen); collagen alpha-3(IV) chain; tumstatin; collagen IV, alpha-3 polypeptide;
COL4A3BP
collagen, type IV, alpha 3 (Goodpasture antigen) binding protein
COL4A3BP; collagen, type IV, alpha 3 (Goodpasture antigen) binding protein; collagen type IV alpha-3-binding protein; ceramide transporter; CERT; GPBP; StAR related lipid transfer (START) domain containing 11; STARD11; hCERT; ceramide transfer protein; li;
DGCR6
DiGeorge syndrome critical region gene 6
DGCR6; DiGeorge syndrome critical region gene 6; protein DGCR6; DGCR 6; DGCR6 protein; DiGeorge syndrome critical region 6; OTTHUMP00000196491; DiGeorge syndrome critical region protein 6;
EBAG9
estrogen receptor binding site associated, antigen, 9
EBAG9; estrogen receptor binding site associated, antigen, 9; receptor-binding cancer antigen expressed on SiSo cells; EB9; RCAS1; cancer associated surface antigen; cancer-associated surface antigen RCAS1; estrogen receptor-binding fragment-associated ge;
EBNA-1
Epstein-Barr virus nuclear antigen 1
EBNA; EBNA-1; Epstein-Barr virus nuclear antigen 1; Epstein-Barr virus; Human herpesvirus 4;
FOLH1
folate hydrolase (prostate-specific membrane antigen) 1
FOLH1; folate hydrolase (prostate-specific membrane antigen) 1; PSM; FGCP; FOLH; GCP2; PSMA; mGCP; GCPII; NAALAD1; NAALAdase; glutamate carboxypeptidase 2; NAALADase I; glutamate carboxylase II; glutamate carboxypeptidase II; membrane glutamate carboxypeptidase; cell growth-inhibiting gene 27 protein; folylpoly-gamma-glutamate carboxypeptidase; prostate specific membrane antigen variant F; pteroylpoly-gamma-glutamate carboxypeptidase; N-acetylated alpha-linked acidic dipeptidase 1; N-acetylated-alpha-linked acidic dipeptidase I;
FOSL1
Fos-related antigen 1
FLJ23306; Fos L2; FOS like antigen 2; Fos related antigen 2; Fos-related antigen 2; FosL 2; Fosl2; FOSL2; FRA 2; FRA-2; Fos-related antigen 1; FOSL1; FRA; FRA1; fra-1;
ITGA4
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
ITGA4; integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor); IA4; CD49D;
Itgal
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1
ITGAL; integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide); CD11A; LFA-1; LFA1A; integrin alpha-L; LFA-1A; LFA-1 alpha; integrin gene promoter; CD11 antigen-like family member A; lymphocyte function-associated antigen 1; leukocyte adhesion glycoprotein LFA-1 alpha chain; leukocyte function-associated molecule 1 alpha chain; antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide;
KAAG1
kidney associated antigen 1
KAAG1;kidney associated antigen 1;21031;ENSG00000146049;RU2AS;6p22.1;MGC78738;kidney-associated antigen 1;kidney-associated antigen 1;RU2 antisense gene protein;
LAMP1
CD107 antigen like family member A
LAMP1; CD107 antigen like family member A; CD107 antigen-like family member A; CD107a; CD107a antigen; LAMP 1; LAMP-1; LAMPA; LGP120; lgpA; Lysosomal membrane glycoprotein 120KD; Lysosomal Associated Membrane Protein 1; Lysosome associated membrane glycoprotein 1; Lysosome-associated membrane glycoprotein 1; Lysosome-associated membrane protein 1; OTTHUMP00000040663;
LY96
lymphocyte antigen 96
LY96; lymphocyte antigen 96; MD2; MD-2; ly-96; ESOP-1; protein MD-2; myeloid differentiation protein-2;
MAGEA1
melanoma antigen family A, 1 (directs expression of antigen MZ2-E)
MAGEA1; melanoma antigen family A, 1 (directs expression of antigen MZ2-E); MAGE1; melanoma-associated antigen 1; cancer/testis antigen family 1; member 1; CT1.1; melanoma antigen family A 1; melanoma antigen MAGE 1; melanoma associated antigen 1; melanoma associated antigen MZ2 E; MGC9326; antigen MZ2-E; MAGE-1 antigen; melanoma antigen MAGE-1; cancer/testis antigen 1.1; melanoma-associated antigen MZ2-E; cancer/testis antigen family 1, member 1;
MAGEA3
melanoma antigen family A, 3
MAGEA3; melanoma antigen family A, 3; MAGE3; melanoma-associated antigen 3; antigen MZ2 D; cancer/testis antigen family 1; member 3; CT1.3; HIP8; HYPD; MAGE 3 antigen; melanoma associated antigen 3; MGC14613; MGC1461; MAGEA6; Melanoma antigen family A 3; antigen MZ2-D; MAGE-3 antigen; cancer/testis antigen 1.3; cancer/testis antigen family 1, member 3;
MAGEA4
melanoma antigen family A, 4
MAGEA4; melanoma antigen family A, 4; MAGE4; melanoma-associated antigen 4; cancer/testis antigen family 1; member 4; CT1.4; MAGE 41; MAGE X2; MAGE4A; MAGE4B; melanoma associated antigen 4; MGC21336; MAGE-4 antigen; MAGE-41 antigen; MAGE-X2 antigen; cance;
MNDA
myeloid cell nuclear differentiation antigen
MNDA; myeloid cell nuclear differentiation antigen; PYHIN3;
NBL1
neuroblastoma, suppression of tumorigenicity 1
NBL1; neuroblastoma, suppression of tumorigenicity 1; neuroblastoma suppressor of tumorigenicity 1; D1S1733E; DAN; DAN domain family member 1; DAND 1; DAND1; Differential screening selected gene aberrant in neuroblastoma; MGC8972; NB; NBL 1; Neuroblastoma candidate region suppression of tumorigenicity 1; Neuroblastoma suppression of tumorigenicity 1; NO 3; NO3; Zinc finger protein DAN; N03; OTTMUSP00000010476; Dana; D4H1S1733E;
PCNA
proliferating cell nuclear antigen
PCNA; proliferating cell nuclear antigen; cyclin; DNA polymerase delta auxiliary protein;
SELP
selectin P (granule membrane protein 140kDa, antigen CD62)
SELP; selectin P (granule membrane protein 140kDa, antigen CD62); GRMP, selectin P (granule membrane protein 140kD, antigen CD62); P-selectin; CD62; CD62P; GMP140; PADGEM; PSEL; GMP-140; granule membrane protein 140; granulocyte membrane protein; CD62 antigen-like family member P; platelet alpha-granule membrane protein; leukocyte-endothelial cell adhesion molecule 3; platelet activation dependent granule-external membrane protein; GRMP; LECAM3; FLJ45155;
SSB
Sjogren syndrome antigen B (autoantigen La)
La; LARP3; La/SSB; La/SSB (Autoimmune RNA Protein); SSB; Sjogren syndrome antigen B (autoantigen La);
ST13
suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein)
ST13; suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein); hsc70-interacting protein; FAM10A1; HIP; HSPABP1; P48; progesterone receptor associated p48 protein; SNC6; Hsp70-interacting protein; aging-associated protein 2; putativ;
SV40gp6
large T antigen
SV40gp6; large T antigen; LT AG; LT; LTAG; binds to the viral origin of replication; regulates the transcription of early region mRNA; helicase activity facilitates movement of the virion DNA replication fork; the small T antigen shares a region in common with the large T antigen;
Thy1
thymus cell antigen 1, theta
THY1; thymus cell antigen 1, theta; thy-1 membrane glycoprotein; Thy 1.2; thy-1 antigen; T25; CD90; Thy-1; Thy1.1; Thy1.2; Thy-1.2;
TSTA3
tissue specific transplantation antigen P35B
TSTA3; tissue specific transplantation antigen P35B; GDP-L-fucose synthase; FX; GDP L fucose synthase; P35B; SDR4E1; short chain dehydrogenase/reductase family 4E; member 1; 3 5 epimerase/4 reductase; anti TSTA3; EC 1.1.1.271; GDP 4 keto 6 deoxy D mannose 35 epimerase 4 reductase; GDP 4 keto 6 deoxy D mannose epimerase reductase; Protein FX; Red cell NADP(H) binding protein; Tissue specific transplantation antigen 3; OTTHUMP00000228670; OTTHUMP00000228671; OTTHUMP00000228672; 3-5 epimerase/4-reductase; red cell NADP(H)-binding protein; GDP-4-keto-6-deoxy-D-mannose epimerase-reductase; GDP-4-keto-6-deoxy-D-manno;
IGHE
Immunoglobulin heavy constant epsilon
immunoglobulin heavy constant epsilon; IgE; IGHE; immunoglobulin gene; IgE; Omalizumab; Xolair; 242138-07-4; Quilizumab; 1228538-47-3;
ITGB1
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
CD29; FNRB; MDF2; VLAB; GPIIA; MSK12; VLA-BETA; integrin beta-1 (avian); ITGB1; integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12);
ITGA2B
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)
ITGA2B; integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41); GT; GTA; CD41; GP2B; HPA3; CD41B; GPIIb; BDPLT2; BDPLT16; integrin alpha-IIb; GPalpha IIb; platelet-specific antigen BAK; platelet membrane glycoprotein IIb; platelet fibrinogen receptor, alpha subunit;
Cd24a
CD24a antigen
CD24A; CD24a antigen; signal transducer CD24; CD 24; CD24; CD24 antigen (small cell lung carcinoma cluster 4 antigen); CD24 antigen; CD24 molecule; CD24_HUMAN; FLJ22950; FLJ43543; GPI linked surface mucin; Heat stable antigen; HSA; MGC75043; Nectadrin; Small cell lung carcinoma cluster 4 antigen; R13-Ag; lymphocyte antigen 52; X62 heat stable antigen; cluster of differentiation 24; M1/69-J11D heat stable antigen; Ly-52;
ITGB3
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
GT; CD61; GP3A; BDPLT2; GPIIIa; integrin beta-3; platelet glycoprotein IIIa; platelet membrane glycoprotein IIIa; CD41; CD41b; GP 2B; GP IIb; GTA; HPA3; Integrin alpha 2b; ITGA2B; ITGB3; Tadocizumab; 339086-80-5;
Cd209a
CD209a antigen
CD209A; CD209a antigen; CIRE; CD209; CDSIGN; Dcsign; SIGNR5; DC-SIGN; SIGN-R1; DC-SIGN1; CD209 antigen-like protein A; dendritic cell-specific ICAM-3-grabbing non-integrin;
ITGAE
integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
ITGAE; integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide); integrin alpha-E; CD103; HUMINAE; HML-1 antigen; integrin alpha-IEL; mucosal lymphocyte 1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha po;
BST2
bone marrow stromal cell antigen 2
BST2; bone marrow stromal cell antigen 2; bone marrow stromal antigen 2; CD317; tetherin; BST-2; NPC-A-7; HM1.24 antigen;
CD81
CD81 antigen
CD81; CD81 antigen; 26 kDa cell surface protein TAPA-1; target of the antiproliferative 1; Tapa1; Tapa-1; Tspan28;
CTAG2
cancer/testis antigen 2
CTAG2; cancer/testis antigen 2; CAMEL; cancer/testis antigen family 6; member 2a; member 2b; CT6.2a; CT6.2b; CTL recognized antigen on melanoma; ESO2; LAGE 1; LAGE 1a; LAGE 1a protein; LAGE 1b; LAGE1; MGC3803; MGC138724; Autoimmunogenic cancer/testis antigen NY ESO 2; Autoimmunogenic cancer/testis antigen NY-ESO-2; Cancer/testis antigen 6.2; CT 2; CT2; CT6.2; CTAG 2; CTAG2_HUMAN; ESO 2; L antigen family member 1; LAGE 2b; LAGE-1; LAGE2b; LAGE-1a protein; OTTHUMP00000026043; OTTHUMP00000026044; CTL-recognized antigen on melanoma; cancer/testis antigen family 6, member 2a; cancer/testis antigen family 6, member 2b; autoim;
EEA1
early endosome antigen 1
EEA1; early endosome antigen 1; MST105; ZFYVE2; MSTP105; early endosome antigen 1, 162kD; endosome-associated protein p162; early endosome-associated protein; zinc finger FYVE domain-containing protein 2;
ELAVL4
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D)
ELAVL4; ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D); HUD; ELAV-like protein 4; PNEM; hu-antigen D; paraneoplastic encephalomyelitis antigen HuD; Embryonic lethal, abnormal vision, Drosophila, homolog of, like-4;
FCER1A
Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide
FCER1A; Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide; FCE1A; high affinity immunoglobulin epsilon receptor subunit alpha; Fc-epsilon RI-alpha; Fc epsilon RI alpha-chain; igE Fc receptor subunit alpha; Fc IgE receptor, alpha polypep;
ICA1
islet cell autoantigen 1, 69kDa
ICA1; islet cell autoantigen 1, 69kDa; islet cell autoantigen 1 (69kD); islet cell autoantigen 1; ICAp69; 69 kDa islet cell autoantigen; Diabetes mellitus type I autoantigen; ICA 1; ICA69; ICA69_HUMAN; Islet cell autoantigen 1 69kDa; Islet cell autoantigen 1 isoform; Islet cell autoantigen p69; OTTHUMP00000200933; OTTHUMP00000200934; OTTHUMP00000200941; OTTHUMP00000200993; p69;
LIMS1
LIM and senescent cell antigen-like domains 1
LIMS1; LIM and senescent cell antigen-like domains 1; PINCH; PINCH1; PINCH-1; LIM and senescent cell antigen-like-containing domain protein 1; renal carcinoma antigen NY-REN-48; particularly interesting new Cys-His protein 1;
LY6H
lymphocyte antigen 6 complex, locus H
LY6H; lymphocyte antigen 6 complex, locus H; lymphocyte antigen 6H; NMLY6; ly-6H;
LY75
LY75 lymphocyte antigen 75
LY75; lymphocyte antigen 75; CD205; CLEC13B; DEC 205; C-type lectin domain family 13 member B; LY-75; DEC-205; GP200-MR6;
LY9
lymphocyte antigen 9
LY9; lymphocyte antigen 9; T-lymphocyte surface antigen Ly-9; cell surface molecule Ly-9; cell-surface molecule Ly-9; Ly-9; T100; CD229; Lgp100; SLAMF3; AI893573;
NOVA1
neuro-oncological ventral antigen 1
NOVA1; neuro-oncological ventral antigen 1; RNA-binding protein Nova-1; ventral neuron-specific protein 1; Nova-1; G630039L02; 9430099M15Rik;
PNMA1
paraneoplastic Ma antigen 1
PNMA1; paraneoplastic Ma antigen 1; paraneoplastic antigen MA1; MA1; 37 kDa neuronal protein; paraneoplastic neuronal antigen MA1; neuron- and testis-specific protein 1;
PNMA2
paraneoplastic antigen MA2
PNMA2; paraneoplastic antigen MA2; MA2; RGAG2; 40 kDa neuronal protein; MM2; Paraneoplastic neuronal antigen; Paraneoplastic neuronal antigen MM2; Retrotransposon gag domain containing 2; onconeuronal antigen MA2;
SP100
SP100 nuclear antigen
SP100; SP100 nuclear antigen; lysp100b; nuclear autoantigen Sp-100; speckled 100 kDa; SP100-HMG nuclear autoantigen; nuclear dot-associated Sp100 protein;
SPAG5
sperm associated antigen 5
SPAG5; sperm associated antigen 5; sperm-associated antigen 5; astrin; DEEPEST; hMAP126; MAP126; mitotic spindle associated protein p126; mitotic spindle coiled coil related protein; hMAP 126; MAP 126; Mitotic spindle associated protein; SPAG 5; Sperm tail protein Spag 5; Sperm tail protein Spag5; OTTHUMP00000233592; mitotic spindle-associated protein p126; mitotic spindle coiled-coil related protein;
SPAG6
sperm associated antigen 6
SPAG6; sperm associated antigen 6; sperm-associated antigen 6; axoneme central apparatus protein; pf16; Repro SA 1; PF16 protein homolog; Protein PF16 homolog; Repro-SA-1; SPAG6_HUMAN; Sperm flagellar protein; OTTHUMP00000019296; OTTHUMP00000019297;
SSSCA1
Sjogren syndrome/scleroderma autoantigen 1
SSSCA1; Sjogren syndrome/scleroderma autoantigen 1; Sjogrens syndrome/scleroderma autoantigen 1; Sjoegren syndrome/scleroderma autoantigen 1; p27; Autoantigen p27; 1500016H19Rik; C184L; centromeric autoantigen (27kD); OTTHUMP00000232769; OTTHUMP00000233069; OTTHUMP00000233071; Sjogrens syndrome/scleroderma autoantigen 1 homolog; SSA27_HUMAN;
ST14
suppression of tumorigenicity 14 (colon carcinoma)
ST14; suppression of tumorigenicity 14 (colon carcinoma); HAI; MTSP1; SNC19; ARCI11; MT-SP1; PRSS14; TADG15; TMPRSS14; suppressor of tumorigenicity 14 protein; prostamin; serine protease 14; serine protease TADG-15; membrane-type serine protease 1; tumor associated differentially expressed gene 15 protein; tumor-associated differentially-expressed gene 15 protein; suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin);
STAG1
stromal antigen 1
STAG1; stromal antigen 1; cohesin subunit SA-1; SA 1; SCC3A; SCC3 homolog 1; nuclear protein stromal antigen 1; SA1; DKFZp781D1416;
STAG2
stromal antigen 2
STAG2; stromal antigen 2; cohesin subunit SA-2; SA 2; SCC3B; SCC3 homolog 2; SA2; SA-2; bA517O1.1; FLJ25871; DKFZp686P168; DKFZp781H1753;
STEAP1
six transmembrane epithelial antigen of the prostate 1
STEAP1; six transmembrane epithelial antigen of the prostate 1; six transmembrane epithelial antigen of the prostate , STEAP; metalloreductase STEAP1; PRSS24; six-transmembrane epithelial antigen of prostate 1; STEAP; MGC19484;
MAGEB18
melanoma antigen family B, 18
MAGEB18; melanoma antigen family B, 18; melanoma-associated antigen B18; MGC33889; B430216B18Rik; MAGBI_HUMAN; MAGE-B18 antigen; MAGEB18 antigen; MGC114496; RGD1560369; RP23-289C5.3;
PNMA3
paraneoplastic antigen MA3
PNMA3; paraneoplastic antigen MA3; MA3; MA5; MGC132756; MGC132758; paraneoplastic cancer testis brain antigen; PNMA 3; PNMA3_HUMAN; paraneoplastic cancer-testis-brain antigen;
FCER2
Fc fragment of IgE, low affinity II, receptor for (CD23)
CD23; FCE2; CD23A; IGEBF; CLEC4J; low affinity immunoglobulin epsilon Fc receptor; BLAST-2; CD23 antigen; fc-epsilon-RII; lymphocyte IgE receptor; immunoglobulin E-binding factor; C-type lectin domain family 4, member J;
CD160
CD160 antigen
CD160; CD160 antigen; natural killer cell BY55; natural killer cell receptor BY55; By55; AU045688;
FCN3
ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen)
FCN3; ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen); ficolin-3; FCNH; HAKA1; Collagen/fibrinogen domain containing lectin 3 p35; Collagen/fibrinogen domain containing protein 3; FCN 3; Ficolin (collagen/fibrinogen domain containing) 3; Ficolin 3; H ficolin; Hakata antigen; MGC22543; H-ficolin; OTTHUMP00000006338; OTTHUMP00000006339; collagen/fibrinogen domain-containing protein 3; collagen/fibrinogen domain-containing lectin 3 p35;
GAGE5
G antigen 5
GAGE5;G antigen 5;cancer/testis antigen family 4;member 5;CT4.5;GAGE-5;cancer/testis antigen 4.5;cancer/testis antigen family 4, member 5;
ITGA3
integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
ITGA3; integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor); antigen identified by monoclonal J143 , MSK18; integrin alpha-3; CD49c; GAP B3; VCA 2; VLA3a; FRP-2; galactoprotein B3; VLA-3 subunit alpha; CD49 antigen-like family member C; antigen identified by monoclonal J143; very late activation protein 3 receptor, alpha-3 subunit; VL3A; GAPB3; MSK18; VCA-2; GAP-B3; FLJ34631; FLJ34704;
MAGEA11
melanoma antigen family A, 11
MAGEA11; melanoma antigen family A, 11; MAGE11; melanoma-associated antigen 11; cancer/testis antigen family 1; member 11; CT1.11; MAGE 11; MAGE 11 antigen; MAGEA 11; melanoma associated antigen 11; MGC10511; MAGE-11 antigen; cancer/testis antigen 1.11; c;
MAGEA2
melanoma antigen family A, 2
MAGEA2; melanoma antigen family A, 2; MAGE2; melanoma-associated antigen 2; cancer/testis antigen family 1; member 2; CT1.2; MAGEA2A; MAGE-2 antigen; melanoma antigen 2; cancer/testis antigen 1.2; cancer/testis antigen family 1, member 2; MAGEA2B; MGC1319;
MAGEA8
melanoma antigen family A, 8
MAGEA8; melanoma antigen family A, 8; MAGE8; melanoma-associated antigen 8; cancer/testis antigen family 1; member 8; CT1.8; MAGE 8 antigen; MGC2182; MAGE8 antigen; Melanoma antigen family A 8; Melanoma associated antigen 8; MAGE-8 antigen; OTTHUMP00000024218; cancer/testis antigen 1.8; cancer/testis antigen family 1, member 8;
MAGEA9
melanoma antigen family A, 9
MAGEA9; melanoma antigen family A, 9; MAGE9; melanoma-associated antigen 9; cancer/testis antigen family 1; member 9; CT1.9; MAGE 9 antigen; melanoma associated antigen 9; MGC8421; MAGE-9 antigen; cancer/testis antigen 1.9; cancer/testis antigen family 1,;
MAGEB1
melanoma antigen family B, 1
MAGEB1; melanoma antigen family B, 1; melanoma-associated antigen B1; cancer/testis antigen family 3; member 1; CT3.1; DAM10; DSS/AHC critical interval MAGE superfamily 10; MAGE Xp; MAGEL1; MGC9322; Cancer/testis antigen 3.1; DSS AHC critical interval MAGE superfamily 10; MAGE B1 antigen; MAGEXP antigen; Melanoma associated antigen B1; MAGE-B1 antigen; MAGE-XP antigen; cancer/testis antigen family 3, member 1; DSS-AHC critical interval MAGE superfamily 10; MAGE-Xp;
MAGEB6
melanoma antigen family B, 6
MAGEB6; melanoma antigen family B, 6; melanoma-associated antigen B6; cancer/testis antigen family 3; member 4; CT3.4; FLJ40242; MAGE B6; MAGEB6A; Cancer/testis antigen 3.4; MAGEB6 antigen; Melanoma associated antigen B6; MAGE-B6 antigen; cancer/testis antigen family 3, member 4; MAGE-B6;
MAGED1
Maged1 melanoma antigen, family D, 1
MAGED1; melanoma antigen, family D, 1; melanoma-associated antigen D1; MAGE-D1 antigen; neurotrophin receptor-interacting MAGE homolog; NRAGE; Dlixin; Dlxin1; Dlxin-1; mFLJ00163; DXBwg1492e; 2810433C11Rik; 5430405L04Rik; FLJ00163;
MAGED2
melanoma antigen family D, 2
MAGED2; melanoma antigen family D, 2; melanoma-associated antigen D2; 11B6; BCG1; breast cancer associated gene 1; HCA10; hepatocellular carcinoma associated protein; hepatocellular carcinoma associated protein HCA10; JCL 1; MAGE D2; MAGED; melanoma assoc;
MAGEH1
melanoma antigen family H, 1
MAGEH1; melanoma antigen family H, 1; melanoma-associated antigen H1; APR1; restin; MAGE-H1 antigen; apoptosis-related protein 1; melanoma antigen, family H, 1 protein; APR-1; MAGEH;
MFI2
antigen p97 (melanoma associated) identified
MFI2; antigen p97 (melanoma associated) identified; melanotransferrin; CD228; FLJ38863; MAP97; membrane bound transferrin like protein; MGC4856; MTF1; Antigen p97; CD228 antigen; Melanoma associated antigen p97; Melanoma-associated antigen p97; TRFM_HUMAN; membrane-bound transferrin-like protein; melanoma-associated antigen p97, isoform 2;
MGEA5
meningioma expressed antigen 5 (hyaluronidase)
MGEA5; meningioma expressed antigen 5 (hyaluronidase); bifunctional protein NCOAT; MEA5; NCOAT; nuclear cytoplasmic O GlcNAcase and acetyltransferase; OGA; Glycoside hydrolase O-GlcNAcase; HAT; HEXC; Hexosaminidase C; Histone acetyltransferase; KIAA0679; Meningioma expressed antigen 5; Meningioma-expressed antigen 5; MGEA 5; N-acetyl-beta-D-glucosaminidase; N-acetyl-beta-glucosaminidase; NCOAT_HUMAN; Nuclear cytoplasmic O-GlcNAcase and acetyltransferase; O-GlcNAcase; hyaluronidase in meningioma;
PAGE1
P antigen family, member 1 (prostate associated)
PAGE1; P antigen family, member 1 (prostate associated); G antigen, family B, 1 (prostate associated) , GAGEB1; G antigen family B member 1; CT16.3; GAGE 9; PAGE 1; G antigen 9; prostate associated gene 1; prostate-associated gene 1 protein; G antigen, fa;
PAGE4
P antigen family, member 4 (prostate associated)
PAGE4; P antigen family, member 4 (prostate associated); G antigen, family C, 1 , GAGEC1; G antigen family C member 1; CT16.7; PAGE 4; FLJ35184; G antigen family C 1; GAGE 9; GAGE9; GAGEC1; JM 27; JM27; P antigen family member 4 (prostate associated); P antigen family member 4; PAGE 1; PAGE1; Prostate associated gene 4 protein; Prostate associated gene protein 4; G antigen, family C, 1; prostate-associated gene 4 protein; prostate-associated gene protein 4; JM-27; GAGE-9; PAGE-1; PAGE-4;
RAGE
renal tumor antigen
RAGE; renal tumor antigen; renal tumor antigen; MOK protein kinase; MOK; MAPK/MAK/MRK overlapping kinase; renal cell carcinoma antigen (MOK protein kinase); Renal tumor antigen 1; EC 2.7.11.22; RAGE1; RAGE-1; OTTHUMP00000227853; OTTHUMP00000227854; OTTHUMP00000227855;
SLC25A16
solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16
SLC25A16; solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16; graves disease carrier protein; D10S105E; GDA; HGT.1; ML7; graves disease autoantigen; solute carrier family 25 member 16; mitochondrial solute carrier prot;
SPA17
sperm autoantigenic protein 17
SPA17; sperm autoantigenic protein 17; sperm surface protein Sp17; cancer/testis antigen 22; CT22; SP17; sperm protein 17; SP17-1;
SPAG4
sperm associated antigen 4
SPAG4;sperm associated antigen 4;sperm-associated antigen 4 protein;acrosomal protein ACR55;cancer/testis antigen 127;CT127;Sad1 and UNC84 domain containing 4;SUN4;sperm tail protein;SUN domain-containing protein 4;outer dense fiber-associated protein SPAG4;
SPAG8
sperm associated antigen 8
SPAG8; sperm associated antigen 8; sperm-associated antigen 8; BS 84; HSD 1; hSMP 1; SPAG3; MGC26201; OTTHUMP00000021352; HSD1; hSMP1; MH SPAG8; OTTMUSP00000032209; SMP1; Sperm associated antigen 8 like protein; Sperm membrane protein 1; OTTHUMP00000215542; OTTHUMP00000215543; OTTHUMP00000215544; OTTHUMP00000215545; sperm membrane protein BS-84; BS-84; HSD-1; hSMP-1;
ST5
suppression of tumorigenicity 5
ST5; suppression of tumorigenicity 5; suppression of tumorigenicity 5 protein; DENN/MADD domain containing 2B; DENND2B; HTS1; p126; DENN domain containing protein 2B; HeLa tumor suppression 1; DENN domain-containing protein 2B; ST 5; ST5_HUMAN;
XAGE2
X antigen family, member 2
XAGE2; X antigen family, member 2; G antigen, family D, 3 , GAGED3; G antigen family D member 3; cancer/testis antigen family 12; member 2; CT12.2; XAGE 2; Cancer/testis antigen 12.2; G antigen family D 3; GAGED3; Protein XAGE 2; Protein XAGE2; X antigen family member 2; XAGE 2 protein; protein XAGE-2; G antigen, family D, 3; cancer/testis antigen family 12, member 2; XAGE-2; XAGE2B;
PSA
prostate specific antigen
Alternative namesAPS; Gamma seminoprotein; Gamma-seminoprotein; hK3; Kallikrein 3; Kallikrein related peptidase 3; Kallikrein-3; KLK 3; KLK2A1; KLK3; KLK3_HUMAN; P 30 antigen; P-30 antigen; P30 antigen; Prostate Specific Antigen; Prostate-specific antigen; Psa; Semenogelase; Seminin;
B-LA
MHC class II antigen alpha
B-LA; MHC class II antigen alpha; DP beta 1 chain; DP(W4) beta chain; DMA; DMB; DP beta 1; DPB 1; DPB1; DPB1_HUMAN; DRB; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DM beta chain; HLA DMB; HLA DPB1; HLA-DPB1; HLADM; HLADP1B; Major histocompatibility complex class II; Major histocompatibility complex class II DP beta 1; MHC class II antigen DMB; MHC class II antigen DPB1; MHC DPB1; RING6; RING7;
CD8B1
CD8 antigen, beta chain 1
CD8B1; CD8 antigen, beta chain 1; T-cell surface glycoprotein CD8 beta chain; CD8b antigen; T cell surface glycoprotein CD8 beta chain; CD8 antigen beta polypeptide 1 (p37); CD8 antigen beta polypeptide 1; CD8 beta; CD8b; CD8b molecule; CD8B_HUMAN; Leu2; Ly3; LYT3; MGC119115; T lymphocyte surface glycoprotein beta chain; lymphocyte antigen 3; T-cell membrane glycoprotein Ly-3; T-cell surface glycoprotein Lyt-3; Ly-3; Ly-C; Lyt-3;
CEACAM19
carcinoembryonic antigen-related cell adhesion molecule 19
CEACAM19; carcinoembryonic antigen-related cell adhesion molecule 19; CEAL1; Carcinoembryonic antigen like 1; Carcinoembryonic antigen related cell adhesion molecule 19; CEA related cell adhesion molecule 19; MGC105097; OTTHUMP00000200169; OTTHUMP00000200170; carcinoembryonic antigen-like 1;
CEACAM20
carcinoembryonic antigen-related cell adhesion molecule 20
CEACAM20; carcinoembryonic antigen-related cell adhesion molecule 20; UNQ9366; carcinoembryonic antigen related cell adhesion molecule 20; GPAD9366;
CEACAM7
carcinoembryonic antigen-related cell adhesion molecule 7
CEACAM7; carcinoembryonic antigen-related cell adhesion molecule 7; CGM2; carcinoembryonic antigen gene family member 2; CEA; Carcinoembryonic antigen CGM 2; Carcinoembryonic antigen CGM2; Carcinoembryonic antigen related cell adhesion molecule 7; CEACAM 7; CGM 2; OTTHUMP00000199040; OTTHUMP00000199041;
DGCR14
DiGeorge syndrome critical region gene 14
DGCR14; DiGeorge syndrome critical region gene 14; DGCR13, DiGeorge syndrome critical region gene 13; protein DGCR14; DGS H; DGSI; ES2; Es2el; DGCR13; DGS I; DGSH; DiGeorge syndrome critical region gene DGSI; DiGeorge syndrome critical region protein 14; DiGeorge syndrome gene H; DiGeorge syndrome gene I; ES2 protein; Protein DGCR13; OTTHUMP00000196363; diGeorge syndrome protein H; diGeorge syndrome critical region 13; diGeorge syndrome critical region 14; DiGeorge syndrome critical region gene 13; DiGeorge syn; DGS-H; DGS-I;
FCER2A
Fc receptor, IgE, low affinity II, alpha polypeptide
FCER2A; Fc receptor, IgE, low affinity II, alpha polypeptide; low affinity immunoglobulin epsilon Fc receptor; Blast 2; BLAST-2; Blast2; C type lectin domain family 4 member J; C-type lectin domain family 4 member J; C-type lectin domain family 4, member J; CD 23; CD 23A; CD23; CD23 Antigen; CD23A; CLEC 4J; CLEC4J; FC Epsilon RII; Fc fragment of IgE low affinity II receptor for; Fc fragment of IgE, low affinity II, receptor for (CD23); Fc of IgE, low affinity II, receptor for (CD23); FC Receptor IgE Low Affinity II Alpha Polypeptide; Fc receptor, IgE, low affinity II, alpha polypeptide, isoform CRA_a; Fc-epsilon-RII; FCE 2; FCE2; FCER 2; Fcer2; FCER2_HUMAN; IgE Binding Factor; IgE Receptor Lymphocyte; IgE-binding factor; IGEBF; Immunoglobulin E binding factor; Immunoglobulin E receptor, low affinity II; Immunoglobulin E-binding factor; Low Affinity immunoglobulin Epsilon FC Receptor Membrane Bound Form; Low Affinity Immunoglobulin Epsilon FC Receptor Soluble Form; Ly-42; Ly42; Lymphocyte antigen CD23; Lymphocyte IgE receptor; MGC93219; low-affinity IgE receptor;
H2-AB1
histocompatibility 2, class II antigen A, beta 1
H2-AB1; histocompatibility 2, class II antigen A, beta 1; Abeta; AI845868; H2 Ab; H2 Ab1; H2 I A beta; Histocompatibility 2 class II antigen A beta 1; Ia2; Iab; MHC class II antigen I A beta 1; Rmcs1; OTTMUSP00000053328; MHC class II H2-IA-beta-psi; MHC class II antigen A beta; response to metastatic cancers 1; major histocompatibility complex class II beta chain; H-2 class II histocompatibility antigen, A be; Ia-2; H-2Ab; H2-Ab; I-Abeta;
H2-EA-PS
histocompatibility 2, class II antigen E alpha, pseudogene
H2-EA-PS; histocompatibility 2, class II antigen E alpha, pseudogene; AI323765; E alpha f; H 2 class II histocompatibility antigen E D alpha chain; H 2Ea; H2 class II histocompatibility antigen E D alpha chain; H2 Ea; H2 Ea histocompatibility 2 class II antigen E alpha; H2 IE alpha; H2Ea; Histocompatibility 2 class II antigen E alpha; I E alpha MHC class II; Ia 3; Ia3; Major histocompatibility complex H 2E alpha chain; MGC117888; MHC class II antigen E alpha; Ia-3; H-2Ea; H2-Ea; I-Ealpha; E-alpha-f;
HHBVgp4
large surface antigen
HHBVgp4; large surface antigen; HBsAg; Hep B surface antigen; Hepatitis B surface antigen; Hepatitis B Virus major surface antigen; Hepatitis B virus S antigen; L glycoprotein; L HBsAg; Large envelope protein; Large S protein; Large surface protein; LHB; Major surface antigen;
INCENP
inner centromere protein antigens 135/155kDa
INCENP; inner centromere protein antigens 135/155kDa; inner centromere protein antigens (135kD, 155kD); inner centromere protein; FLJ31633; chromosomal passenger protein; inner centromere protein INCENP; binds and activates aurora-B and -C in vivo and in;
KIN
KIN, antigenic determinant of recA protein homolog (mouse)
KIN; KIN, antigenic determinant of recA protein homolog (mouse); antigenic determinant of recA protein (mouse) homolog; DNA/RNA-binding protein KIN17; KIN17; Binding to curved DNA; BTCD; HsKin17 protein; KIN antigenic determinant of recA protein homolog mouse; Kin17 protein; OTTHUMP00000019061; antigenic determinant of recA protein homolog;
LOC649783
similar to HLA class II histocompatibility antigen, DRB1-8 beta chain precursor (MHC class I antigen DRB1*8) (DR-8) (DR8) (DRw8)
LOC649783; similar to HLA class II histocompatibility antigen, DRB1-8 beta chain precursor (MHC class I antigen DRB1*8) (DR-8) (DR8) (DRw8);
LY6A
lymphocyte antigen 6 complex, locus A
LY6A; lymphocyte antigen 6 complex, locus A; TAP; Sca-1; Ly-6A.2; Ly-6A/E; Ly-6E.1;
LY6B
lymphocyte antigen 6 complex, locus B
LY6B; lymphocyte antigen 6 complex, locus B; Lymphocyte antigen 6B Short name=Ly-6B;
LY6C1
lymphocyte antigen 6 complex, locus C1
LY6C1; lymphocyte antigen 6 complex, locus C1; Ly6c; Ly-6C; Ly-6C1; AA682074; AA959465; lymphocyte antigen 6C1; Lymphocyte antigen Ly-6C; lymphocyte antigen 6 complex, locus C;
LY6G
lymphocyte antigen 6 complex, locus G
LY6G; lymphocyte antigen 6 complex, locus G; Gr1; Gr-1; Ly-6G;
MAGEA12
melanoma antigen family A, 12
MAGEA12; melanoma antigen family A, 12; MAGE12; melanoma-associated antigen 12; cancer/testis antigen family 1; member 12; CT1.12; MAGE-12 antigen; MAGE12F antigen; cancer/testis antigen 1.12; cancer/testis antigen family 1, member 12;
MAGEC1
melanoma antigen family C, 1
MAGEC1; melanoma antigen family C, 1; melanoma-associated antigen C1; cancer/testis antigen family 7; member 1; CT7; CT7.1; MAGE C1; MGC39366; MAGE-C1 antigen; cancer/testis antigen 7.1; cancer/testis antigen family 7, member 1;
MUM1
melanoma associated antigen (mutated) 1
MUM1; melanoma associated antigen (mutated) 1; PWWP domain-containing protein MUM1; MUM 1; protein expandere; melanoma ubiquitous mutated protein; mutated melanoma-associated antigen 1; MUM-1; EXPAND1; HSPC211; FLJ14868; FLJ22283; MGC131891; MGC163315;
RHCE
Rh blood group, CcEe antigens
Blood group RhCcEe antigen; CD240CE; CD240CE antigen; RH; Rh blood group antigen Evans; Rh blood group C antigen; Rh blood group, CcEe antigens; Rh polypeptide 1; Rh polypeptide I; RH30A; Rh4; RHC; RHCE blood group variant Crawford antigen Rh43; RHE; Rhesus blood group CE protein; Rhesus blood group E antigen; Rhesus blood group Rhce antigen; Rhesus blood group, CcEe antigens; Rhesus C/E antigens; Rhesus system C and E polypeptides; RhIVb(J); RHIXB; RHPI; RhVI; RhVIII;
SPAG9
sperm associated antigen 9
SPAG9; sperm associated antigen 9; JLP; CT89; HLC4; HLC6; JIP4; PHET; PIG6; HLC-6; JIP-4; C-Jun-amino-terminal kinase-interacting protein 4; sunday driver 1; Max-binding protein; sperm surface protein; lung cancer oncogene 4; JNK interacting protein; cancer/testis antigen 89; JNK/SAPK-associated protein; proliferation-inducing gene 6; protein highly expressed in testis; human lung cancer oncogene 6 protein; mitogen-activated protein kinase 8-interacting protein 4; c-Jun NH2-terminal kinase-associated leucine zipper protein;
SSNA1
Sjogren syndrome nuclear autoantigen 1
SSNA1; Sjogren syndrome nuclear autoantigen 1; Sjogrens syndrome nuclear autoantigen 1; Sjoegren syndrome nuclear autoantigen 1; N14; NA14; NA 14; Nuclear autoantigen of 14 kDa; SSNA 1; OTTHUMP00000022691; NA-14;
YFV
MHC class I antigen
YFV; MHC class I antigen; A-3 alpha chain; 1A03_HUMAN; HLA A; HLA class I; HLA class I histocompatibility antigen; HLA-A; HLAA; Leukocyte antigen class I A; Major histocompatibility complex, class I, A; MHC class I antigen A; MHC class I antigen A*3; MHC class I antigen HLA A heavy chain; class I alpha chain; Y-FA;
SAG
SAG S-antigen; retina and pineal gland (arrestin)
SAG; S-antigen; retina and pineal gland (arrestin); S-arrestin; ARRESTIN; arrestin 1; 48 kDa protein; rod photoreceptor arrestin; retinal S-antigen (48 KDa protein); RP47; S-AG; DKFZp686D1084; DKFZp686I1383;
GAGE1
G antigen 1
GAGE1; G antigen 1; cancer/testis antigen family 4; member 1; CT4.1; Cancer/testis antigen 4.1; CT4 1; GAGE 1; MZ2 F antigen; MZ2-F antigen; cancer/testis antigen family 4, member 1; GAGE-1;
MAGEA6
melanoma antigen family A, 6
MAGEA6; melanoma antigen family A, 6; MAGE6; melanoma-associated antigen 6; cancer/testis antigen family 1; member 6; CT1.6; MAGE 6 antigen; melanoma antigen family A 6; melanoma associated antigen 6; Cancer/testis antigen 1.6; MAGA6_HUMAN; MAGE 3b; MAGE-6 antigen; MAGE3B; MAGE3B antigen; OTTHUMP00000024223; OTTHUMP00000024224; OTTHUMP00000205538; cancer/testis antigen family 1, member 6; MAGE-3b;
RHD
D Antigen Rh Typing
Rh blood group, D antigen; RHCED; CD240D; RHDVA(TT); DIIIc; RHDel; RH; RHPII; Rh4; RhDCw; RhII; RhK562-II; RhPI1; blood group Rh(D) polypeptide; Rh polypeptide 2; D antigen (DCS); Rhesus D antigen; Rh blood group antigen Evans; RHXIII; Rhesus blood group D antigen allele DIII type 7; Rh30a; Rhesus system D polypeptide; Rhesus blood group, D antigen; RhPII; RH30; CD240D antigen; Rhesus D antigen; RHD; Rh blood group, D antigen; RH; RHPI; Atorolimumab; 202833-08-7; Morolimumab; 202833-07-6; Roledumab; 1174008-79-7;
SDCCAG8
serologically defined colon cancer antigen 8
SDCCAG8; serologically defined colon cancer antigen 8; BBS16; CCCAP; NPHP10; NY CO 8; SLSN7; Antigen NY CO 8; Centrosomal colon cancer autoantigen protein; HSPC085; NPHP10 gene; NY-CO-8; Serologically defined colon cancer antigen 8 homolog; SLSN7 gene; antigen NY-CO-8; hCCCAP;
LOC425256
similar to class II histocompatibility antigen B-L beta chain (clone p14)
similar to class II histocompatibility antigen B-L beta chain (clone p14);
ICA1L
islet cell autoantigen 1,69kDa-like
ICA1L; islet cell autoantigen 1,69kDa-like; ALS2CR14, ALS2CR15, amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 14 , amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 15; islet cell autoantigen 1-like protein; ALS2CR14; ALS2CR15 protein; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 15 protein; amyotrophic lateral sclerosis 2 juvenile chromosome region candidate 14; amyotrophic lateral sclerosis 2 juvenile chromosome region candidate 15; DKFZp434E1919; Hypothetical protein DKFZp434E1919; Ica69 related protein; Ica69-related protein; islet cell autoantigen 1 69kDa-like; LOC130026; MGC138440; amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 14; amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 15; amyotrophic lateral sclerosis 2 chromosomal region candidate gene 14 protein; ALS2CR15;
BAGE2
B melanoma antigen family, member 2
BAGE2; B melanoma antigen family, member 2; B melanoma antigen 2; cancer/testis antigen family 2; member 2; CT2.2; cancer/testis antigen 2.2; cancer/testis antigen family 2, member 2;
BAGE3
B melanoma antigen family, member 3
BAGE3; B melanoma antigen family, member 3; B melanoma antigen 3; cancer/testis antigen family 2; member 3; CT2.3; cancer/testis antigen 2.3; cancer/testis antigen family 2, member 3;
BAGE4
B melanoma antigen family, member 4
BAGE4; B melanoma antigen family, member 4; MLL3 pseudogene , MLL3P; B melanoma antigen 4; cancer/testis antigen family 2; member 4; CT2.4; BAGE4_HUMAN; Cancer/testis antigen 2.4; MGC119851; MGC119852; MGC119853; MLL3P; MLL3 pseudogene; cancer/testis antigen family 2, member 4;
CAGE1
cancer antigen 1
CAGE1; cancer antigen 1; cancer/testis antigen 3 , CTAG3; cancer-associated gene 1 protein; bA69L16.7; cancer/testis antigen 95; CT95; cancer/testis antigen 3; cancer/testis antigen gene 1; CT3; CTAG3; FLJ40441;
CEACAM4
carcinoembryonic antigen-related cell adhesion molecule 4
CEACAM4; carcinoembryonic antigen-related cell adhesion molecule 4; CGM7; carcinoembryonic antigen CGM7; nonspecific cross-reacting antigen W236; Nonspecific cross-reacting antigen (NCA); non-specific cross-reacting antigen W236; carcinoembryonic antigen;
CEACAM21
carcinoembryonic antigen-related cell adhesion molecule 21
CEACAM21; carcinoembryonic antigen-related cell adhesion molecule 21; FLJ13540; R29124_1; Carcinoembryonic antigen related cell adhesion molecule 21; CEA21_HUMAN; CEACAM3; MGC119874; OTTHUMP00000199036;
FCER1G
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide
FCER1G; Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide; high affinity immunoglobulin epsilon receptor subunit gamma; fcRgamma; fceRI gamma; fc-epsilon RI-gamma; Fc receptor gamma-chain; immunoglobulin E receptor, high affinity, gamma;
CT45A3
cancer/testis antigen family 45, member A3
CT45A3; cancer/testis antigen family 45, member A3; cancer/testis antigen family 45 member A3; cancer/testis antigen CT45 3; CT45 3; CT45.3; Cancer/testis antigen 45-3; Cancer/testis antigen 45A3; CT453_HUMAN; cancer/testis antigen CT45-3; CT45-3; RP13-36C9.1; RP13-36C9.3;
CT45A4
cancer/testis antigen family 45, member A4
CT45A4; cancer/testis antigen family 45, member A4; cancer/testis antigen family 45 member A4/A6; cancer/testis antigen CT45 4; CT45 4; CT45.4; Cancer/testis antigen 45-4/6; Cancer/testis antigen 45A4/45A6; CT45-4; CT454_HUMAN; CT45A6; cancer/testis antigen CT45-4;
DGCR6L
DiGeorge syndrome critical region gene 6-like
DGCR6L; DiGeorge syndrome critical region gene 6-like; protein DGCR6L; FLJ10666; DGC6L_HUMAN; DiGeorge syndrome critical region 6-like protein; DiGeorge syndrome critical region gene 6 like;
DIEXF
digestive organ expansion factor homolog (zebrafish)
DIEXF; digestive organ expansion factor homolog (zebrafish); C1orf107, chromosome 1 open reading frame 107; digestive organ expansion factor homolog; DEF; MGC29875; UTP25; C1orf107; DIEXF_HUMAN; DJ434O14.5; OTTHUMP00000034820; digestive-organ expansion factor homolog;
GAGE12H
G antigen 12H
GAGE12H; G antigen 12H; OTTHUMG00000024149; GAGE-12H; GG12H_HUMAN; RP11-959H17.7;
LAGE3
L antigen family, member 3
LAGE3; L antigen family, member 3; L antigen family member 3; CVG5; DNA segment on chromosome X (unique) 9879 expressed sequence; DXS9879E; DXS9951E; ESO3; ITBA2; protein ESO-3;
LIMS2
LIM and senescent cell antigen-like domains 2
LIMS2; LIM and senescent cell antigen-like domains 2; LIM and senescent cell antigen-like-containing domain protein 2; FLJ10044; LIM-like protein 2; LIMS2_HUMAN; Particularly interesting new Cys-His protein 2; PINCH-2; ILK-binding protein; PINCH2;
LY6K
lymphocyte antigen 6 complex, locus K
LY6K; lymphocyte antigen 6 complex, locus K; lymphocyte antigen 6K; ly-6K; mLy-6K; 2410015A16Rik; 3110035B01Rik;
MAGEB4
melanoma antigen family B, 4
MAGEB4; melanoma antigen family B, 4; melanoma-associated antigen B4; cancer/testis antigen family 3; member 6; CT3.6; melanoma associated antigen B4; MGC33144; MAGE-B4 antigen; cancer/testis antigen family 3, member 6;
SPECC1
sperm antigen with calponin homology and coiled-coil domains 1
SPECC1; sperm antigen with calponin homology and coiled-coil domains 1; cytospin-B; cytokinesis and spindle organization B; cytospin B; CYTSB; FLJ36955; HCMOGT 1; NSP; sperm antigen HCMOGT 1; NSP5; sperm antigen HCMOGT-1; structure protein NSP5a3a; struct;
LY6E
lymphocyte antigen 6 complex, locus E
LY6E; lymphocyte antigen 6 complex, locus E; lymphocyte antigen 6E; retinoic acid induced gene E; RIG E; SCA 2; TSA 1; Ly 6E; Ly6A.2; Ly6A/E; Ly6E.1; Lymphocyte antigen 6 complex locus A; Lymphocyte antigen 6 complex locus E; OTTHUMP00000227386; OTTHUMP00000227387; OTTHUMP00000227407; OTTHUMP00000227411; OTTHUMP00000227413; OTTHUMP00000227414; OTTHUMP00000227415; OTTHUMP00000227416; OTTHUMP00000227418; OTTHUMP00000227419; Retinoic acid induced gene E protein; RIGE; Sca1; Sca2; Stem cell antigen 1; Stem cell antigen 2; T cell activating protein; TAP; Thymic shared antigen 1; TSA1; ly-6E; retinoic acid-induced gene E protein; RIG-E; SCA-2; TSA-1;
MAGEB3
melanoma antigen family B, 3
MAGEB3; melanoma antigen family B, 3; melanoma-associated antigen B3; cancer/testis antigen family 3; member 5; CT3.5; Cancer/testis antigen family 3 member 5; MAGB3_HUMAN; MAGE B3 antigen; MAGE-B3 antigen; Melanoma associated antigen B3; cancer/testis antigen family 3, member 5;
LOC554223
histocompatibility antigen-related
LOC554223; histocompatibility antigen-related; Hypothetical LOC554223; LOC554223 protein;
LY6G5B
lymphocyte antigen 6 complex, locus G5B
LY6G5B; lymphocyte antigen 6 complex, locus G5B; C6orf19, chromosome 6 open reading frame 19; lymphocyte antigen 6 complex locus protein G5b; G5b; C6orf19; Casein kinase II subunit beta; Chromosome 6 open reading frame 19; CK II beta; CK2N; G5A; Phosvitin; lymphocyte antigen-6 G5B;
LY6G6C
lymphocyte antigen 6 complex, locus G6C
LY6G6C; lymphocyte antigen 6 complex, locus G6C; C6orf24, chromosome 6 open reading frame 24; lymphocyte antigen 6 complex locus protein G6c; G6c; NG24; lymphocyte antigen-6 G6C; C6orf24;
LY6G6F
lymphocyte antigen 6 complex, locus G6F
LY6G6F; lymphocyte antigen 6 complex, locus G6F; C6orf21, chromosome 6 open reading frame 21 , LY6G6D; lymphocyte antigen 6 complex locus protein G6f; G6f; NG32; lymphocyte antigen 6 complex, locus G6D; LY6G6D; C6orf21;
MINA
MYC induced nuclear antigen
MINA; MYC induced nuclear antigen; ROX; MDIG; NO52; MINA53; bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA; nucleolar protein 52; ribosomal oxygenase MINA; histone lysine demethylase MINA; mineral dust induced gene protein; mineral dust-induced gene protein; myc-induced nuclear antigen, 53 kDa; 60S ribosomal protein L27a histidine hydroxylase;
MAGEA10
melanoma antigen family A, 10
MAGEA10; melanoma antigen family A, 10; MAGE10; melanoma-associated antigen 10; cancer/testis antigen family 1; member 10; CT1.10; MAGE 10 antigen; melanoma associated antigen 10; MGC10599; MAGE-10 antigen; cancer/testis antigen 1.10; cancer/testis antige;
MAGEA5
melanoma antigen family A, 5
MAGEA5; melanoma antigen family A, 5; MAGE5; melanoma-associated antigen 5; cancer/testis antigen family 1; member 5; CT1.5; MAGE 5a antigen; MAGE 5b antigen; MGC129526; Cancer/testis antigen 1.5; Cancer/testis antigen family 1 member 5; MAGE 5 antigen; MAGEA4; Melanoma antigen family A 5; Melanoma associated antigen 5; MAGE-5 antigen; MAGE-5a antigen; MAGE-5b antigen; cancer/testis antigen family 1, member 5;
MAGEB17
melanoma antigen family B, 17
MAGEB17; melanoma antigen family B, 17; melanoma antigen family B, 17 (pseudogene); MAGBH_HUMAN; Melanoma-associated antigen B17;
MAGEB2
melanoma antigen family B, 2
MAGEB2; melanoma antigen family B, 2; melanoma-associated antigen B2; cancer/testis antigen family 3; member 2; CT3.2; DAM6; DSS/AHC critical interval MAGE superfamily 6; MAGE XP 2; melanoma associated antigen B2; MGC26438; MAGE-B2 antigen; MAGE XP-2 anti;
MAGEC2
melanoma antigen family C, 2
MAGEC2; melanoma antigen family C, 2; MAGEE1, melanoma antigen, family E, 1, cancer/testis specific; melanoma-associated antigen C2; cancer/testis antigen 10; CT10; MAGE C2; Cancer testis antigen 10; HCA587; Hepatocellular carcinoma associated antigen 587; Hepatocellular carcinoma-associated antigen 587; MAGC2_HUMAN; MAGE C2 antigen; MAGE E1 antigen; MAGE-C2 antigen; MAGE-E1 antigen; Melanoma associated antigen C2; MGC13377; hepatocellular cancer antigen 587; melanoma antigen, family E, 1, cancer/testis specific; MAGEE1;
MAGEF1
melanoma antigen family F, 1
MAGEF1; melanoma antigen family F, 1; melanoma-associated antigen F1; MAGE-F1 antigen; MGC19617;
MUM1L1
melanoma associated antigen (mutated) 1-like 1
MUM1L1; melanoma associated antigen (mutated) 1-like 1; PWWP domain-containing protein MUM1L1; FLJ33516; MUM1-like protein 1; mutated melanoma-associated antigen 1-like protein 1; MGC129994; MGC129995;
NASP
nuclear autoantigenic sperm protein (histone-binding)
NASP; nuclear autoantigenic sperm protein (histone-binding); nuclear autoantigenic sperm protein; DKFZp547F162; FLB7527; FLJ31599; FLJ35510; MGC2297; MGC19722; MGC20372; PRO1999; 5033430J04Rik; AI131596; AI317140; D4Ertd767e; Epcs32; MGC93869; NASP_HUMAN; nuclear autoantigenic sperm protein (histone binding); RP23 233B9.9; histone H1-binding protein;
NOVA2
neuro-oncological ventral antigen 2
NOVA2; neuro-oncological ventral antigen 2; NOVA3; RNA-binding protein Nova-2; ANOVA; neuro oncological ventral antigen 3; neuro-oncological ventral antigen 3; astrocytic NOVA1-like RNA-binding protein;
PION
pigeon homolog
PION; pigeon homolog (Drosophila); gamma-secretase-activating protein; LOC54103; protein pigeon homolog; GSAP; MGC126548; DKFZp667B242;
PNMAL1
paraneoplastic Ma antigen family-like 1
PNMAL1; paraneoplastic Ma antigen family-like 1; PNMA like 1; PNMA-like protein 1; FLJ10781; KIAA1183L; PNMA-like 1;
PRAME
preferentially expressed antigen in melanoma
PRAME; preferentially expressed antigen in melanoma; MAPE; melanoma antigen preferentially expressed in tumors; cancer/testis antigen 130; CT130; 4930534P07Rik; OIP 4; OIP-4; OIP4; OPA interacting protein 4; Opa interacting protein OIP4; OPA-interacting protein 4; PRAME_HUMAN; Preferentially expressed antigen of melanoma; RP23-250F8.3; Opa-interacting protein OIP4;
RALY
RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse))
RALY; RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse)); RNA binding protein (autoantigenic, hnRNP associated with lethal yellow); RNA-binding protein Raly; HNRPCL2; P542; Autoantigen p542; Heterogeneous nuclear ribonucleoprotein C-like 2; hnRNP associated with lethal yellow protein homolog; hnRNP core protein C-like 2; MGC117312; RALY_HUMAN; RNA binding protein (autoantigenic hnRNP associated with lethal yellow); RNA binding protein (autoantigenic); RNA binding protein autoantigenic (hnRNP associated with lethal yellow homolog (mouse)); RNA-binding protein (autoantigenic); RNA-binding protein (autoantigenic, hnRNP-associated with lethal yellow);
eba-165
erythrocyte binding antigen-165
eba-165; erythrocyte binding antigen-165; erythrocyte binding antigen putative;
PNKD
paroxysmal nonkinesigenic dyskinesia
PNKD; paroxysmal nonkinesigenic dyskinesia; paroxysmal nonkinesiogenic dyskinesia; probable hydrolase PNKD; BRP17; DKFZp564N1362; DYT8; FKSG19; FPD1; KIAA1184; KIPP1184; MGC31943; MR 1; myofibrillogenesis regulator 1; PDC; PKND1; TAHCCP2; brain protein 17; trans-activated by hepatitis C virus core protein 2; MR1; MR-1;
SPECC1L
sperm antigen with calponin homology and coiled-coil domains 1-like
SPECC1L; sperm antigen with calponin homology and coiled-coil domains 1-like; SPECC1 like; cytospin-A; cytokinesis and spindle organization A; cytospin A; CYTSA; KIAA0376; CYTSA_HUMAN; Renal carcinoma antigen NY-REN-22; SPECC1-like protein; OBLFC1;
SART1
squamous cell carcinoma antigen recognized
SART1; squamous cell carcinoma antigen recognized; squamous cell carcinoma antigen recognised by T cells; U4/U6.U5 tri-snRNP-associated protein 1; Ara1; small nuclear ribonucleoprotein 110kDa (U4/U6.U5); SNRNP110; Snu66; Ara 1; HOMS 1; HOMS1; hSART 1; hSART1; hSnu 66; hSnu66; IgE autoantigen; SART 1; SART1 259; SART1(259) protein; SART1(800) protein; SART1259; Snu 66; Squamous cell carcinoma antigen recognized by T cells 1; U4/U6.U5 tri snRNP associated 110 kDa protein; U4/U6.U5 tri snRNP associated protein 1; SART-1; hSART-1; SNU66 homolog; U4/U6.U5 tri-snRNP-associated 110 kDa protein;
SART3
squamous cell carcinoma antigen recognized
SART3; squamous cell carcinoma antigen recognized; squamous cell carcinoma antigen recognised by T cells 3; squamous cell carcinoma antigen recognized by T-cells 3; KIAA0156; RP11 13G14; hSART 3; p110(nrb); RP11-13G14; Tat interacting protein of 110 kDa; TIP110; SART-3; hSART-3; tat-interacting protein of 110 kDa; P100; p110; DSAP1;
TINAG
tubulointerstitial nephritis antigen
TINAG; tubulointerstitial nephritis antigen; TIN AG; TIN-Ag; TIN1; TIN2; TINAG_HUMAN;
TINAGL1
tubulointerstitial nephritis antigen-like 1
TINAGL1; tubulointerstitial nephritis antigen-like 1; LCN7, lipocalin 7 , TINAG like 1; tubulointerstitial nephritis antigen-like; ARG1; LIECG3; P3ECSL; TINAGRP; Androgen regulated gene 1; GIS5; Glucocorticoid inducible protein 5; Glucocorticoid inducible protein; LCN7; Lipocalin 7; Lipocalin7; OLRG 2; OLRG2; Oxidized LDL responsive gene 2; Oxidized LDL responsive gene 2 protein; TIN Ag related protein; TIN Ag RP; TINAG like 1; TINAGL 1; TINAGL; Tubulointerstitial nephritis antigen like 1; Tubulointerstitial nephritis antigen like; Tubulointerstitial nephritis antigen related protein; OLRG-2; TIN-Ag-RP; TINAG-like 1; TIN Ag-related protein; androgen-regulated gene 1; oxidized-LDL responsive gene 2; glucocorticoid-inducible protein 5; tubulointerstitial nephritis antigen-related protein;
STAG3
stromal antigen 3
STAG3; stromal antigen 3; cohesin subunit SA-3; Cohesin subunit SA 3; Cohesin subunit SA3; SCC3 homolog 3; Stromalin 3; stromalin-3;
GATS
GATS, stromal antigen 3 opposite strand
GATS; GATS, stromal antigen 3 opposite strand; putative protein GATS; DKFZp686B07267; STAG3OS; stromal antigen 3 opposite strand; STAG3 opposite strand transcript protein; opposite strand transcription unit to STAG3;
SPAG11A
sperm associated antigen 11A
SPAG11A; sperm associated antigen 11A; sperm-associated antigen 11A; EDDM2A; epididymal protein 2A; HE2; EP2; Bin1b; EP2e; EP2Q; Spag11; 9230111C08Rik; Human epididymis-specific protein 2; Protein EP2; SG11A_HUMAN; Sperm antigen HE2;
SPAG11B
sperm associated antigen 11B
SPAG11B; sperm associated antigen 11B; sperm-associated antigen 11B; EDDM2B; EP2; EP2C; EP2D; epididymal protein 2B; HE2; Epididymal protein 2; HE2C; Protein EP2; SPAG11; Sperm antigen HE2; Sperm associated antigen 11; human epididymis-specific protein 2;
SPAG16
sperm associated antigen 16
SPAG16; sperm associated antigen 16; sperm-associated antigen 16 protein; DKFZp666P1710; FLJ22724; PF20; WDR29; WD repeat domain 29; pf20 protein homolog; sperm-associated WD repeat protein; FLJ37717; MGC87036;
LY6D
lymphocyte antigen 6 complex, locus D
LY6D; lymphocyte antigen 6 complex, locus D; lymphocyte antigen 6D; ly-6D; thymocyte B-cell antigen; Thb; Ly61; Ly-61;
UACA
uveal autoantigen with coiled-coil domains and ankyrin repeats
UACA; uveal autoantigen with coiled-coil domains and ankyrin repeats; FLJ10128; KIAA1561; MGC141967; MGC141969; NUCLING; Uveal autoantigen with coiled coil domains and ankyrin repeats; nuclear membrane binding protein;
XAGE1D
X antigen family, member 1D
XAGE1D; X antigen family, member 1D; G antigen family D member 2; cancer/testis antigen family 12; member 1d; CT12.1d; G antigen family D 2 protein; GAGED2; X antigen family, member 1; protein XAGE-1; cancer/testis antigen 12.1; cancer/testis associated protein; cancer/testis antigen family 12, member 1d; CTP9; CT12.1; XAGE1A; XAGE1B; XAGE1C; XAGE1E;
XAGE5
X antigen family, member 5
XAGE5; X antigen family, member 5; G antigen, family D, 5 , GAGED5; G antigen family D member 5; cancer/testis antigen family 12; member 5; CT12.5; XAGE 5; GAGED5; MGC119799; MGC119800; Cancer/testis antigen 12.5; GAGD5_HUMAN; Protein XAGE-5; RP13-77O11.4; G antigen, family D, 5; cancer/testis antigen family 12, member 5; XAGE-5;
CEACAM16
carcinoembryonic antigen-related cell adhesion molecule 16
CEACAM16; carcinoembryonic antigen-related cell adhesion molecule 16; Carcinoembryonic antigen like 2; Carcinoembryonic antigen like 2 protein; Carcinoembryonic antigen related cell adhesion molecule 16; CEAL2; carcinoembryonic antigen-like 2; carcinoembryonic antigen like-2 protein;
SDCCAG3
serologically defined colon cancer antigen 3
SDCCAG3; serologically defined colon cancer antigen 3; NY CO 3; antigen NY-CO-3; NY-CO-3;
HBx
HEPATITIS B Virus X Antigen
HBV X antigen; HBx; HBxAg; Hepatitis B Virus X antigen; Hepatitis B Virus X; HBV X; HBVX;
XAGE1A
X antigen family, member 1A
XAGE1A;X antigen family, member 1A;4111;ENSG00000204379;CTP9;XAGE1;CT12.1;GAGED2;CT12.1A;Xp11.22;G antigen family D member 2;G antigen family D member 2;protein XAGE-1;cancer/testis antigen 12.1;cancer/testis associated protein;cancer/testis antigen family 12, member 1a;
anthrax PA
Bacillus anthracis protective antigen
anthrax PA; Anthrax Protective Antigen; Anthrax toxins translocating protein; Bacillus anthracis Protective Antigen; PA 83; PA; PA83; Pag; PagA; Protective antigen;
H2-Aa
histocompatibility 2, class II antigen A, alpha
H2-AA;histocompatibility 2, class II antigen A, alpha;ENSMUSG00000036594;Ia1;H2Aa;Ia-1;H-2Aa;Aalpha;IAalpha;I-Aalpha;17 B1;17 18.65 cM;histocompatibility 2, class II antigen A, alpha;histocompatibility 2, class II antigen A, alpha;A alpha;MHC-II I-A(d) alpha;MHC class II antigen;major histocompatibility protein class II alpha chain;H-2 class II histocompatibility antigen, A-B alpha chain;H-2 class II histocompatibility antigen, A-F alpha chain;H-2 class II histocompatibility antigen, A-K alpha chain;H-2 class II histocompatibility antigen, A-Q alpha chain;H-2 class II histocompatibility antigen, A-R alpha chain;H-2 class II histocompatibility antigen, A-S alpha chain;H-2 class II histocompatibility antigen, A-U alpha chain;
LY6G5C
lymphocyte antigen 6 complex, locus G5C
LY6G5C;lymphocyte antigen 6 complex, locus G5C;13932;ENSG00000204428;G5C;NG33;C6orf20;LY6G5CA;LY6G5CB;6p21.33;lymphocyte antigen 6 complex locus protein G5c;lymphocyte antigen 6 complex locus protein G5c;lymphocyte antigen-6 G5C;
MEA1
male-enhanced antigen 1
MEA1;male-enhanced antigen 1;6986;ENSG00000124733;HYS;MEA;6p21.3-p21.1;male-enhanced antigen 1;male-enhanced antigen 1;MEA-1;Male-enhanced antigen (H-Y structural gene);
SPAG17
sperm associated antigen 17
SPAG17;sperm associated antigen 17;26620;ENSG00000155761;PF6;RP4-776P7.2;1p12;FLJ34497, FLJ44343, FLJ44353, DKFZp434B0610;sperm-associated antigen 17;sperm-associated antigen 17;projection protein PF6 homolog;
SPAG7
sperm associated antigen 7
SPAG7;sperm associated antigen 7;11216;ENSG00000091640;ACRP;FSA-1;17p13.2;MGC20134;sperm-associated antigen 7;sperm-associated antigen 7;
ST18
suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)
ST18;suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein);18695;ENSG00000147488;ZNF387;8q11.23;KIAA0535;suppression of tumorigenicity 18 protein;suppression of tumorigenicity 18 protein;zinc finger protein 387;
ST7L
suppression of tumorigenicity 7 like
ST7L;suppression of tumorigenicity 7 like;18441;ENSG00000007341;ST7R;STLR;FAM4B;1p13.2;FLJ11657, FLJ20284;suppressor of tumorigenicity 7 protein-like;suppressor of tumorigenicity 7 protein-like;ST7-related protein;tumor suppressor ST7 like;
ETAA1
Ewing tumor-associated antigen 1
ETAA1;Ewing tumor-associated antigen 1;24648;ENSG00000143971;ETAA16;2p14;FLJ22647;ewings tumor-associated antigen 1;ewings tumor-associated antigen 1;ETAA16;ewings tumor-associated antigen 16;
ELAVL3
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C)
ELAVL3;ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C);3314;ENSG00000196361;HUC;HUCL;PLE21;19p13.2;MGC20653, DKFZp547J036;ELAV-like protein 3;ELAV-like protein 3;Hu antigen C;hu-antigen C;paraneoplastic limbic encephalitis antigen 21;paraneoplastic cerebellar degeneration-associated antigen;
Ceacam12
carcinoembryonic antigen-related cell adhesion molecule 12
Ceacam12C1; Ceacam12C3; Ceacam12-C1; Ceacam12-C3; 1600031J20Rik;
Ceacam14
carcinoembryonic antigen-related cell adhesion molecule 14
AV033953; 1600021E03Rik; 1600025E09Rik;
GAGE7
GAGE7 G antigen 7 [ Homo sapiens ]
G antigen 7; 4104; G antigen 12G; cancer/testis antigen 4.7; cancer/testis antigen family 4, member 7; AL4; CT4.7; GAGE-7;
LOC288521
similar to Leukosialin precursor (Leucocyte sialoglycoprotein) (Sialophorin) (CD43) (W3/13 antigen)
MGC112692
similar to Leukosialin precursor (Leucocyte sialoglycoprotein) (Sialophorin) (CD43) (W3/13 antigen)
Dgcr2
DGCR2 DiGeorge syndrome critical region gene 2 [ Homo sapiens ]
DGS C; DGS2; DiGeorge syndrome critical region gene 2; IDD; integral membrane protein DGCR2; LAN; SEZ 12; DiGeorge syndrome critical region protein 2; integral membrane protein deleted in DiGeorge syndrome;
GAGE2D
GAGE2D G antigen 2D [ Homo sapiens ]
G antigen 2D; 31959; Ensembl:ENSG00000240257; MGC26395; cancer/testis antigen 4.8; CT4.8; GAGE8; GAGE-8; GAGE-2D;
LOC688090
similar to RT1 class II histocompatibility antigen, B-1 beta chain precursor (RT1.B-beta(1))
CD66a
carcinoembryonic antigen-related cell adhesion molecule 1
Bgp; Cc1; Hv2; Bgp1; Cea1; Cea7; Hv-2; MHVR; bb-1; C-CAM; CD66a; Cea-1; Cea-7; MHVR1; Mhv-1; mCEA1; mmCGM1; mmCGM2; mmCGM1a;
CD66c
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)
NCA; CEAL; CD66c;
CTAGE1
CTAGE1 cutaneous T-cell lymphoma-associated antigen 1 [ Homo sapiens (human) ]
Cancer/testis antigen 21.2; Cancer/testis antigen family 21 member 1; Cancer/testis antigen family 21 member 2; CT21.2; CTAGE 1; CTAGE 2; CTAGE; CTAGE1; CTGE2_HUMAN; Cutaneous T cell lymphoma associated antigen 1; Cutaneous T cell lymphoma associated antigen 2; Protein cTAGE-2;
Protective antigen of anthrax toxin
Protective antigen of anthrax toxin
anthrax PA; Anthrax Protective Antigen; Anthrax toxins translocating protein; Bacillus anthracis Protective Antigen; PA 83; PA; PA83; Pag; PagA; Protective antigen;
CA 19-9
Cancer Antigen 19-9
CA19-9; carbohydrate antigen 19-9; cancer antigen 19-9; sialylated Lewis (a) antigen); Sialyl Lewis (a); Sialyl Lewisa;
Epigenetics-Based Assay Development
As one of the booming fields, epigenetics bridges genotype to phenotype and provides in-depth understanding of aging, human development, the origins of cancer, metabolic diseases, heart disease, mental illness, as well as several other diseases. Post-translational modifications of histones, together...
Patients with Digestive Diseases Gain Hope for Selective Therapies by Targeting Specific Neurotransmitter
Recently, Penn State College of Medicine researchers did some studies regarding neuroscience. They found separate nerve pathways regulate diverse organ functions along the upper gastrointestinal (GI) tract, which is different from what researchers found in past studies. The lead investigator of this...
Soligenix Collaborates with Intrexon on Promoting Monoclonal Antibody Therapy for Melioidosis
On May 1, 2013, Soligenix, Inc., a biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures announced its collaboration between Intrexon to develop a treatment for Melioidosis. Intrexon is a synthetic biology company that utilizes its...
Angiopoietin-1 Was Found to Has Control over Fish Brain Size and Intelligence
Recently, a new study conducted by scientists at UCL, Stockholm University and University of Helsinki found that a single gene called Angiopoietin-1(Ang-1) controls brain size and intelligence in fish. Scientists in this study employed guppi...
